Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Altimmune ( (ALT) ) has issued an announcement.
On November 5, 2025, Altimmune, Inc. amended its Loan and Security Agreement with Hercules Capital, increasing the available term loan from $100 million to $125 million, with an extended interest-only period. The company also announced financial results for Q3 2025, highlighting a cash position of $211 million and a net loss of $19 million. Altimmune is advancing its pemvidutide program for MASH, AUD, and ALD, with significant milestones expected by year-end, including an End-of-Phase 2 meeting with the FDA and the release of 48-week data from the IMPACT trial. The company has strengthened its executive team with key appointments and completed patient enrollment in the RECLAIM trial ahead of schedule.
The most recent analyst rating on (ALT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily influenced by its financial challenges and valuation concerns, which are offset to some extent by positive developments in clinical trials and a strong cash position as highlighted in the earnings call. The technical analysis suggests a neutral market stance, providing neither strong bullish nor bearish signals.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases.
Average Trading Volume: 2,777,525
Technical Sentiment Signal: Sell
Current Market Cap: $331.8M
Find detailed analytics on ALT stock on TipRanks’ Stock Analysis page.